Showing results (171-180 of 257) with videos related to
Sort By:
Pageof 26
Eclinicalmedicine|August 21, 2023
Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 studyPier Luigi Zinzani, Marek Trněný, Vincent Ribrag, et al.Blood|July 25, 2008
Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistanceIlaria Iacobucci, Annalisa Lonetti, Francesca Messa, et al.Leukemia & Lymphoma|November 4, 2014
Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemiaJaspal Kaeda, Frauke Ringel, Christian Oberender, et al.The Lancet. Haematology|January 27, 2020
Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 studyJean-Jacques Kiladjian, Pierre Zachee, Masayuki Hino, et al.American Journal of Hematology|April 10, 2026
A Real-Life Multicenter Study of Checkpoint Inhibitors in Relapsed/Refractory Primary Mediastinal B-Cell LymphomaGabriele Gugliotta, Lisa Argnani, Martina Cantelli, et al.Haematologica|October 8, 2008
Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing methodIlaria Iacobucci, Annalisa Lonetti, Daniela Cilloni, et al.Blood|August 9, 2011
SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemiaNicola Esposito, Irene Colavita, Concetta Quintarelli, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity studyJorge E Cortes, Michele Baccarani, François Guilhot, et al.Blood|April 1, 2011
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working PartyGabriele Gugliotta, Fausto Castagnetti, Francesca Palandri, et al.Cancers|February 15, 2022
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela StudyBeatrice Casadei, Lisa Argnani, Alessandro Broccoli, et al.Pageof 26